Payment overview · 2025
General Payments
$451.63
10 reported records · 7 companies
Healthcare provider profile · identity verified
Mark Victor Restad, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · KENAI, AK · NPI 1114145174
Verified facts
What the public records show
CMS Open Payments records show Mark Victor Restad, PA-C received $451.63 in general payments during 2025 across 10 reported records.
AstraZeneca Pharmaceuticals LP accounted for 39.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $177.43 | 39.3% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $125.00 | 27.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.14 | 12.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.74 | 6.4% | 1 | 2025 |
| 3B Medical, Inc. | Unresolved — no canonical attribution shown | $26.67 | 5.9% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $22.66 | 5.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.99 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $451.63 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $57.14 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $52.43 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $28.74 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $28.74 | 1 | 2025 |
Source payment records
|
|||||
| LUNA Normalized: luna |
Device | 3B Medical, Inc. | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 172 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 170 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 151 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 143 | 30 |
| Gabapentin | Gabapentin | 141 | 29 |
| Metformin Hcl | Metformin Hcl | 131 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 126 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 26 |
| Omeprazole | Omeprazole | 114 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 111 | 28 |
| Tramadol Hcl | Tramadol Hcl | 108 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 22 |
| Simvastatin | Simvastatin | 89 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 25 |
| Ozempic | Semaglutide | 81 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 19 |
| Potassium Chloride | Potassium Chloride | 71 | 14 |
| Furosemide | Furosemide | 70 | 19 |
| Clonidine Hcl | Clonidine Hcl | 69 | 18 |
| Pregabalin | Pregabalin | 69 | 15 |
| Methadone Hcl | Methadone Hcl | 67 | suppressed |
| Diazepam | Diazepam | 66 | 18 |
| Losartan Potassium | Losartan Potassium | 65 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 39 |
| Oxycodone Hcl | Oxycodone Hcl | 60 | suppressed |
| Eliquis | Apixaban | 57 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 13 |
| Azithromycin | Azithromycin | 55 | 42 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | suppressed |
| Memantine Hcl | Memantine Hcl | 52 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 12 |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 48 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 16 |
| Montelukast Sodium | Montelukast Sodium | 46 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 43 | suppressed |
| Jardiance | Empagliflozin | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | 14 |
| Alprazolam | Alprazolam | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | suppressed |
| Carvedilol | Carvedilol | 31 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 30 | 12 |
| Buprenorphine Hcl | Buprenorphine Hcl | 29 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 21 |
| Baclofen | Baclofen | 26 | suppressed |
| Clonidine | Clonidine | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 18 |
| Estradiol | Estradiol | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 12 |
| Torsemide | Torsemide | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 14 |
| Lidocaine | Lidocaine | 17 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Mitigare | Colchicine | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $451.63 · 10 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAMZYOS, EVENITY, GVOKE HYPOPEN, LUNA, PROLIA, SUBLOCADE, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error